Establishment of a histiocytic sarcoma cell line and anti-tumor effect of bortezomib in the African pygmy hedgehog ( Atelerix albiventris)

被引:0
作者
Inanaga, Sakuya [1 ]
Shimoda, Hiroshi [2 ]
Igase, Masaya [1 ]
Kondo, Hirotaka [3 ]
Koizumi, Iori [2 ,4 ]
Mizuno, Takuya [1 ]
机构
[1] Yamaguchi Univ, United Grad Sch Vet Med, Lab Mol Diagnost & Therapeut, 677-1 Yoshida, Yamaguchi, Yamaguchi 7538511, Japan
[2] Yamaguchi Univ, United Grad Sch Vet Med, Lab Vet Microbiol, Yamaguchi, Japan
[3] Nihon Univ, Dept Vet Med, Lab Vet Pathol, Kanagawa, Japan
[4] Koizumi Nest Anim Hosp, Fukuoka, Japan
关键词
African pygmy hedgehog ( Atelerix albiventris); bortezomib; histiocytic sarcoma; proteasome inhibitor; tumor; MULTIPLE-MYELOMA; PROTEASOME; APOPTOSIS; STRESS; CHOP;
D O I
10.1292/jvms.23-0426
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
The African pygmy hedgehog ( Atelerix albiventris) is known to have a high incidence of tumor. However, investigating the tumors of this species has been constrained by the limited availability of research materials such as cell lines and genome information. In this study, we successfully established a novel cell line from a histiocytic sarcoma (HS) of an African pygmy hedgehog, allowing us to conduct a drug screening. We investigated using FDA-approved drug library screening to determine which anticancer drug this tumor cell line is sensitive to, and as a result of apoptosis experiments, bortezomib among the three proteasome inhibitors was found to induce cell death of cancer cells by significantly increasing caspase-3 cleavage (P<0.01). P <0.01). Thus, we elucidated that the proteasome inhibitors, particularly bortezomib, exhibit anti-tumor effects on a cell line derived from an HS in an African pygmy hedgehog through a mechanism comparable to that described in human tumors. This study reports the first characterized cell line from the African pygmy hedgehog and also highlights the potential utility of bortezomib as an anti-tumor treatment for HS in this species.
引用
收藏
页码:833 / 840
页数:8
相关论文
共 33 条
  • [1] The proteasome: A suitable antineoplastic target
    Adams, J
    [J]. NATURE REVIEWS CANCER, 2004, 4 (05) : 349 - 360
  • [2] How many species of mammals are there?
    Burgin, Connor J.
    Colella, Jocelyn P.
    Kahn, Philip L.
    Upham, Nathan S.
    [J]. JOURNAL OF MAMMALOGY, 2018, 99 (01) : 1 - 14
  • [3] Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group
    Chen, Christine I.
    Kouroukis, C. Tom
    White, Darrell
    Voralia, Michael
    Stadtmauer, Edward
    Stewart, A. Keith
    Wright, John J.
    Powers, Jean
    Walsh, Wendy
    Eisenhauer, Elizabeth
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) : 1570 - 1575
  • [4] THE UBIQUITIN-PROTEASOME PROTEOLYTIC PATHWAY
    CIECHANOVER, A
    [J]. CELL, 1994, 79 (01) : 13 - 21
  • [5] Dimopoulos M, 2020, LANCET, V396, P186, DOI 10.1016/S0140-6736(20)30734-0
  • [6] Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome
    Finley, Daniel
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 2009, 78 : 477 - 513
  • [7] Protein degradation and protection against misfolded or damaged proteins
    Goldberg, AL
    [J]. NATURE, 2003, 426 (6968) : 895 - 899
  • [8] Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
    Hajek, Roman
    Bryce, Richard
    Ro, Sunhee
    Klencke, Barbara
    Ludwig, Heinz
    [J]. BMC CANCER, 2012, 12
  • [9] Heatley JF, 2005, SEMIN AVIAN EXOT PET, V14, P182, DOI 10.1016/j.saep.2005.07.002
  • [10] Hideshima T, 2001, CANCER RES, V61, P3071